Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CanSino Coronavirus Vaccine Approved For Military Use In China

But May Not Portend Public Use Nod

Executive Summary

The move may signal China is accelerating the vaccine to hit the general market soon, but a false impression of the vaccine’s safety may be potentially misleading, says one regulatory expert.

You may also be interested in...



CanSino Moving Coronavirus Vaccine To Phase III

CanSino plans to start a Phase III study soon for its candidate with a 40,000 enrollment target, discloses its co-founder.

Quick Listen: Scrip’s Five Must-Know Things

Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.

Coronavirus Update: WHO Aims For 2 Billion Doses, Oral Vaccine Selected For Warp Speed

As vaccine development progresses, worldwide deaths caused by SARS-CoV-2 continue to rise, and now exceed 500,000, with more than 10 million confirmed cases. Daily new infections also hit a new peak, as some US states are being forced to consider lockdowns again as the situation worsens.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC142485

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel